KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Total Liabilities: 2019-2025

Historic Total Liabilities for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $9.7 billion.

  • Royalty Pharma's Total Liabilities rose 24.96% to $9.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 billion, marking a year-over-year increase of 24.96%. This contributed to the annual value of $7.9 billion for FY2024, which is 25.13% up from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's Total Liabilities is $9.7 billion, which was up 10.28% from $8.8 billion recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Total Liabilities registered a high of $9.7 billion during Q3 2025, and its lowest value of $6.1 billion during Q1 2021.
  • Its 3-year average for Total Liabilities is $7.6 billion, with a median of $7.8 billion in 2024.
  • As far as peak fluctuations go, Royalty Pharma's Total Liabilities surged by 184.84% in 2021, and later decreased by 13.59% in 2023.
  • Quarterly analysis of 5 years shows Royalty Pharma's Total Liabilities stood at $7.3 billion in 2021, then rose by 0.29% to $7.3 billion in 2022, then decreased by 13.59% to $6.3 billion in 2023, then increased by 25.13% to $7.9 billion in 2024, then climbed by 24.96% to $9.7 billion in 2025.
  • Its last three reported values are $9.7 billion in Q3 2025, $8.8 billion for Q2 2025, and $7.8 billion during Q1 2025.